GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Return-on-Tangible-Asset

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Return-on-Tangible-Asset : 17.32% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. China Resourcesnjiu Medical & Pharmaceutical Co's annualized Net Income for the quarter that ended in Mar. 2024 was ¥5,455 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2024 was ¥31,506 Mil. Therefore, China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 17.32%.

The historical rank and industry rank for China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:000999' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 10.17   Med: 12.81   Max: 14.81
Current: 10.18

During the past 13 years, China Resourcesnjiu Medical & Pharmaceutical Co's highest Return-on-Tangible-Asset was 14.81%. The lowest was 10.17%. And the median was 12.81%.

SZSE:000999's Return-on-Tangible-Asset is ranked better than
81.18% of 1084 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs SZSE:000999: 10.18

China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Asset Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.78 10.17 12.35 12.82 11.12

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.80 9.98 7.13 5.97 17.32

Competitive Comparison of China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset falls into.



China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Asset Calculation

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2852.932/( (20378.032+30946.275)/ 2 )
=2852.932/25662.1535
=11.12 %

China Resourcesnjiu Medical & Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=5455.304/( (30946.275+32065.009)/ 2 )
=5455.304/31505.642
=17.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


China Resourcesnjiu Medical & Pharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines